Shares in Redx Pharma were under pressure today following the announcement that it would not be advancing its cancer drug candidate RXC004 into phase 3 testing in biliary tract cancer, after it failed ...

I am going to take a deep dive into Redx Pharma Plc’s (LON:REDX) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of a company has ...

It ain’t over ‘til it’s over and for Redx Pharma, it’s over. Redx and Jounce Therapeutics announced Monday morning that the two companies agreed to terminate their proposed business combination ...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise well ...

There’s significant change on the way at Jounce Therapeutics. The embattled clinical-stage company announced Wednesday afternoon that it is laying off more than half of its workforce as part of a ...

A $425 million proposed marriage between Redx Pharma of the UK and Jounce Therapeutics is on the rocks, just over a month after it was first announced. Jounce has instead thrown its lot in with ...

Jazz Pharmaceuticals has struck a deal to source two targeted cancer therapies from Redx Pharma. Redx will pocket $10 million upfront, with more to follow, in return for developing candidates against ...

Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development ...

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announced that ...

Simply sign up to the UK companies myFT Digest -- delivered directly to your inbox. Trading of shares in Redx, a UK pharmaceuticals company, resumed after five months on Monday when the slimmed-down ...